ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KAI vs TMO // GROSS PROFIT MARGIN

Kadant Inc (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: KAI 5 — TMO 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KAI VS. TMO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KAI TMO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 45.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 14.40% 9.30% +5.10 KAI /roic <GO>
EV/EBITDA & P/E Valuation 18.0x 30.4x -12.40 KAI /valuation <GO>
Free Cash Flow Yield 4.81% 2.40% +2.41 KAI /fcf-yield <GO>
Operating Margin 14.90% 17.40% -2.50 TMO /operating-margins <GO>
Net Profit Margin 9.70% 15.10% -5.40 TMO /net-margins <GO>
Revenue Growth (YoY) -0.10% 3.90% -4.00 TMO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.49% 0.24% +0.25 KAI /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 4.50 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 TMO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.7 62.9 -16.24 TMO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.94 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 29.2x 36.3x -7.10 KAI /forward-pe <GO>
Enterprise Scale & Market Cap $3.20B $262.22B -$259.01B TMO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KAI REV TMO REV KAI GROSS % TMO GROSS % KAI FCF TMO FCF
FY 2025 $1.05B $44.56B 45.2% — $154.3M $6.29B
FY 2024 $1.05B $42.88B 44.3% — $134.3M $7.27B
FY 2023 $957.7M $42.86B — — $165.5M $6.48B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KAI // BETA —
TMO // BETA 0.94